- Home
- LYRA vs YHC Comparison
LYRA vs YHC Comparison
Compare LYRA & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- YHC
- Stock Information
- Founded
- LYRA 2005
- YHC 2021
- Country
- LYRA United States
- YHC United States
- Employees
- LYRA N/A
- YHC N/A
- Industry
- LYRA Medical/Dental Instruments
- YHC Beverages (Production/Distribution)
- Sector
- LYRA Health Care
- YHC Consumer Staples
- Exchange
- LYRA Nasdaq
- YHC Nasdaq
- Market Cap
- LYRA 13.5M
- YHC 12.3M
- IPO Year
- LYRA 2020
- YHC N/A
- Fundamental
- Price
- LYRA $0.19
- YHC $1.36
- Analyst Decision
- LYRA Buy
- YHC
- Analyst Count
- LYRA 5
- YHC 0
- Target Price
- LYRA $4.50
- YHC N/A
- AVG Volume (30 Days)
- LYRA 1.9M
- YHC 501.3K
- Earning Date
- LYRA 11-12-2024
- YHC 11-14-2024
- Dividend Yield
- LYRA N/A
- YHC N/A
- EPS Growth
- LYRA N/A
- YHC N/A
- EPS
- LYRA N/A
- YHC N/A
- Revenue
- LYRA $1,471,000.00
- YHC $2,272,001.00
- Revenue This Year
- LYRA N/A
- YHC N/A
- Revenue Next Year
- LYRA N/A
- YHC N/A
- P/E Ratio
- LYRA N/A
- YHC N/A
- Revenue Growth
- LYRA 3.37
- YHC 158.05
- 52 Week Low
- LYRA $0.16
- YHC $0.40
- 52 Week High
- LYRA $6.79
- YHC $2.83
- Technical
- Relative Strength Index (RSI)
- LYRA 46.20
- YHC N/A
- Support Level
- LYRA $0.18
- YHC N/A
- Resistance Level
- LYRA $0.22
- YHC N/A
- Average True Range (ATR)
- LYRA 0.02
- YHC 0.00
- MACD
- LYRA -0.00
- YHC 0.00
- Stochastic Oscillator
- LYRA 16.31
- YHC 0.00
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.